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Patients with paroxysmal nocturnal hemoglobinuria have a high frequency
of peripheral-blood T cells expressing activating isoforms of inhibiting
superfamily receptors
Alessandro Poggi, Simone Negrini, Maria Raffaella Zocchi, Anna-Maria Massaro, Lucia Garbarino, Sonia Lastraioli, Lucia Gargiulo,
Lucio Luzzatto, and Rosario Notaro
Patients with paroxysmal nocturnal hemo-
globinuria (PNH) have a large clonal popu-
lation of blood cells deriving from hema-
topoietic stem cells (HSCs) deficient in
glycosylphosphatidylinositol (GPI)–
anchored surface molecules. A current
model postulates that PNH arises through
negative selection against normal HSCs
exerted by autoreactive T cells, whereas
PNH HSCs escape damage. We have in-
vestigated the inhibitory receptor super-
family (IRS) system in 13 patients with
PNH. We found a slight increase in the
proportion of T cells expressing IRS. In
contrast to what applies to healthy do-
nors, the engagement of IRS molecules
on T cells from patients with PNH elicited
a powerful cytolytic activity in a redi-
rected killing assay, indicating that these
IRSs belong to the activating type. This
was confirmed by clonal analysis: 50% of
IRS T-cell clones in patients with PNH
were of the activating type, while only 5%
were of the activating type in healthy
donors. Moreover, the ligation of IRS in-
duces (1) production of tumor necrosis
factor  (TNF-) and interferon  (IFN-)
and (2) brisk cytolytic activity against
cells bearing appropriate IRS counter-
ligands. In addition, these IRS T cells
show natural killer (NK)–like cytolytic ac-
tivity to which GPI cells were less sensi-
tive than GPI cells. Thus, T cells with
NK-like features, expressing the activat-
ing isoforms of IRS, may include effector
cells involved in the pathogenesis of PNH.
(Blood. 2005;106:2399-2408)
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Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal disorder
of the hematopoietic stem cell (HSC)1 characterized by an acquired
somatic mutation in the PIG-A gene2,3; this results in a deficiency
on the cell membrane of all proteins anchored by the glycosylphos-
phatidylinositol (GPI) molecules.4,5 PNH is closely related to
idiopathic aplastic anemia (IAA),6,7 which in turn is thought to
result from an auto immune attack against HSCs.8 Indeed, thorough
analysis of the T-cell repertoire has revealed an increased frequency
of expanded T-cell clones in both PNH9,10 and IAA.10,11 This set of
facts could be interpreted as suggesting that in PNH autoreactive T
cells cause the selective destruction of normal HSCs, whereas
HSCs with a PIG-A mutation and consequently with a GPI
phenotype can escape T-cell–mediated damage, thus being able to
survive and expand.12-14 The identity of the putative autoreactive T
cells and of their molecular targets remain unknown.
Recent studies have identified a subset of peripheral-blood T
lymphocytes expressing on their surface molecules that are mem-
bers of the inhibitory receptor superfamily (IRS), including killer
immunoglobulin (Ig)–like receptor (KIR, CD158) or C-lectin type
inhibitory receptors (CLIRs, CD94/NKG2).15-17 Upon interaction
with HLA-I expressed on autologous cells, these IRSs can deliver
an inhibitory signal leading to the reduction of cytolytic activity as
well as to the inhibition of cytokine secretion.18-20 This inhibitory
effect is mediated by the association of IRS with tyrosine phospha-
tases, such as Src homology 2–containing protein tyrosine phospha-
tase-1 (SHP-1), which in turn block the positive signal delivered by
activating T-cell surface molecules.15-17 In addition to the inhibitory
isoforms of IRS, activating isoforms also exist.15-17 The engage-
ment of activating IRS leads to activation of effector-cell functions
including cytolytic activity, cytokine production, and prolifera-
tion.15-24 In healthy donors, IRS T lymphocytes express surface
markers characteristic of memory T cells.25,26 Thus, it has been
proposed that this T-cell subset may be expanded in the course of
long-term stimulation (eg, in certain viral infections and autoim-
mune processes).27 Interestingly, it has been reported that T cells
bearing activating isoforms of IRS are increased in the sinovial
fluid of patients with rheumatoid arthritis, suggesting that these
cells may play a role in the pathogenesis of this disease.24 Indeed, T
cells bearing activating IRS may actually recognize self–major
histocompatibility complex (MHC) alleles and thus activate autoim-
mune reaction.
We have characterized IRS T cells in patients with PNH, and
we have found distinctive qualitative abnormalities. The engage-
ment of IRS molecules on cells belonging to this T-cell subset
induced triggering of cytolytic activity and production of cyto-
kines. This indicates that the IRS T-cell population found in
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patients with PNH, in contrast to healthy donors, tends to bear
IRS of activating type, which may be involved in the pathogene-
sis of PNH.
Patients, materials, and methods
Subjects
Blood samples from 13 patients with hemolytic PNH (median age, 45 years;
range, 24-55 years) and from 38 healthy individuals (median age, 42 years;
range, 28-50 years) were collected after informed consent was obtained
according to National Institute for Cancer Research (IST-Genoa) institu-
tional procedure. We included only patients with primary classic PNH who
had a large PNH population (GPI granulocytes over 40%), florid
hemoglobinuria, and no severe cytopenias (Table 1). No patient was
receiving any immunosuppressive drug at the time of the study. Few
patients have been studied during the follow-up with blood sampling about
3 months apart.
Cell separation and analysis
Mononuclear peripheral-blood cells (PBMCs) were isolated by density
gradient centrifugation (Ficoll Hypaque; Sigma, St Louis, MO) as de-
scribed28 and used in immunofluorescence and functional assays. Absolute
number of CD3KIR or CD3KIR or CD3CLIR or CD3CLIR
lymphocytes was calculated on the basis of lymphocyte counts and the
percentage of each cell population determined after surface staining with
the corresponding antibodies and analysis on a FACSort (Becton Dickin-
son, Palo Alto, CA).
Monoclonal antibodies (mAbs) and reagents
The anti-CD16 (NK54, IgG1) mAb, the anti-CD56 (TA181H12, IgG2a)
mAb, the anti-CD54 (14D12D2, IgG1) mAb, the anti-CD3 (JT3A, IgG2a)
mAb, the anti-CD8 (astra102, IgG1) mAb, the pan KIR2D NKVFS1 mAb
(recognizing a common epitope of CD158a/h and of CD158b/j), and p50.3
(CD158i) were produced as described.15,28,29 The anti-CD3 (Leu4, IgG1),
anti-CD4 (Leu3a, IgG1), and anti-CD8 (Leu2a, IgG1) mAbs were from
Becton Dickinson. The anti-CD94 (HP-3B1, IgG2a; or E94, IgG1),
anti-CD158a/h (KIR2DL1/S1) (EB6, IgG1), and anti-CD158b/j (KIR2DL2/
S2) (GL183, IgG1) mAbs were from Serotec (Kidlington, Oxford, United
Kingdom). The affinity-purified goat antimouse (GAM) anti-isotype spe-
cific antiserum was from Southern Biotechnology (Birmingham, AL).
Purified GAM anti-Ig (HL) was purchased from Sigma. The EasySep
Custom kit was purchased from Stemcell Biotechnologies (Vancouver, BC,
Canada). Recombinant interleukin 2 (rIL2) was from Chiron (Proleukin;
Chiron Italia, Siena, Italy). Cells were cultured in RPMI 1640 medium with
glutamine and pennicillin-streptomycin (Biochrom, Berlin, Germany)
supplemented with 10% fetal calf serum (FCS; Sigma).
Indirect immunofluorescence
Immunofluorescence staining was performed as described.28 Briefly, ali-
quots of 105 cells were stained with the indicated mAbs followed by either
the fluorescein isothiocyanate (FITC)– or phycoerythrin (PE)–conjugated
anti–isotype-specific GAM antiserum or with an unrelated mAb followed
by the fluorescent second reagent. Samples were analyzed on a flow
cytometer (FACSort; Becton Dickinson) equipped with a 488-nm argon ion
laser exciting FITC, PE, or peridinin chlorophyll (PerCP), and results are
expressed as Log green (x-axis) versus red (y-axis) mean fluorescence
intensity (MFI) in arbitrary units (au). In some experiments triple immuno-
fluorescence staining was performed with anti–CD3-PerCP, anti–CD94-PE
(HP-3B1), and Leu7-FITC– or CD8-FITC–conjugated mAbs. Then samples
were run on a FACSort by gating either CD3CD94 or CD3CD94 cells.
Generation of T-cell clones expressing IRS
CD3 IRS T cells were isolated from PBMCs of patients with PNH or
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and custom preparation of EasySep (Stemcell Biotechnologies). The
resulting cell population was 60% to 90% CD94 and 50% to 95% CD3
depending on the donor. Purified CD94 cells were stimulated with 10
g/mL phytohemagglutinin (PHA) and cultured in 96-well U-bottomed
microplates (Becton Dickinson) with complete medium in the presence of
100 U/mL rIL2 in a final volume of 200 L/well in the presence of 105/well
irradiated allogeneic PBMCs and 5  103/well 721.221 lymphoblastoid
cell line transfected with HLA-G.30 CD3 T-cell clones were obtained by
culturing purified CD94 cells under limiting dilution conditions as
previously reported.29,30 Briefly, CD94 cells were cultured in U-bottomed
plates at different numbers of cells per well (25/well, 10/well, 5/well,
1/well, and 0.5/well) in the presence of 105 irradiated PBMCs and 103
irradiated 721.221 HLA-I–negative lymphoblastoid cell line with 1 g/mL
PHA and 100 IU/mL IL2. After 5 days medium was changed and cell
proliferation was detected from day 10 of culture. Cloning efficiency
ranged from 10% to 30%, calculated as described.31 All cell populations
were analyzed for the expression of CD3, CD94/NKG2, CD16, CD56,
KIR2DL1/S1 with EB6 mAb, and KIR2DL2/S2 with GL183 mAb. For the
expression of KIR2DS4, cells reacted with NKVFS1 mAb but not with EB6
and GL183 mAbs. Each clone was analyzed in a redirected killing assay
using the FcR P815 murine mastocytoma cell line in the presence of
mAbs recognizing either KIR (anti-CD158 mAb, NKVFS1) or CLIR
(anti-CD94 mAb, E94) at the effector-to-target (E/T) ratio of 20:1 or 2:1 to
identify clones with inhibiting or activating forms of these HLA-I receptors,
respectively.30 Indeed, when the engagement of either KIR or CLIR
triggered cytolysis of P815 at a 2:1 E/T ratio, that clone was assigned to the
activating group. On the other hand, when cytolysis of P815 at a 20:1 E/T
ratio was inhibited by the addition of either anti-KIR or anti-CLIR mAb,
that clone expressed IRS of the inhibiting type.30
Determination of IFN- and TNF- in culture supernatants
Interferon  (IFN-) and tumor necrosis factor  (TNF-) released in
culture supernatant from T-cell clones derived from PBMCs of patients with
PNH upon incubation for 24 hours with medium alone, or in the presence of
anti-IRS or anti-CD3 mAbs followed by GAM to obtain optimal cross-
linking of the corresponding surface molecule, as indicated in “Results,”
was evaluated by enzyme-linked immunosorbent assay (ELISA; Pepro-
Tech, London, United Kingdom).32
Cytolytic assays
Cytolytic activity of either ex vivo–isolated PBMCs from patients with
PNH or healthy donors or from T-cell clones was tested in a 4-hour
51Cr-release assay as previously described.28,29 T-cell clones were selected
for the expression of activating forms of either KIR and/or CLIR, and were
used as effector cells with the FcR murine mastocytoma cell line P815 in
the presence of mAb directed against activating receptor for HLA, at an E/T
ratio of 2:1, in a final volume of 200 L RPMI 1640 medium in V-bottomed
microwells.28,29 In order to confirm that killing of target cells by an IRS
T-cell population or by a T-cell clone is mediated by the ligation of an
activating type IRS to its cognate HLA ligand, we used the HLA-I–negative
lymphoblastoid cell line 721.221. These cells were transfected either with
HLA-G (to induce expression of HLA-E with HLA-G peptides, as
appropriate for the CD94/NKG2 complex of activating type); or with
HLA-Cw3 (appropriate for CD158h [KIR2D2S1]); or with HLA-Cw4
(appropriate for CD158j [KIR2DS2]). These cells were then used without
and with the addition of either anti–HLA-I or anti-IRS mAb (5 g/mL). In
some experiments, to study the spontaneous cytolytic activity of IRS T
cells, GPI K562 erythroleukemia cell line (K562wt) and the parental K562
cell line lacking GPI-linked surface molecules (KCRN) generated by
Finberg and collaborators33 were used in cytolytic assays with IRS T cells
from patients with PNH. To evaluate the contribution of GPI-linked
molecules to the interaction between effector and K562 target cells, the
experiments were carried out also in the presence of saturating amounts of
anti-LFA1 mAb (5 g/mL).
Analysis of KIR genotype and HLA-I typing in patients with PNH
High-molecular-weight DNA was extracted from peripheral-blood samples
by a standard method. KIR genotyping was performed by using a multiplex
polymerase chain reaction (PCR) method developed by Sun et al.34 PCR
amplification was performed with hot-start DNA polymerase, AmpliTaq
Gold (Applied Biosystems), by using the described PCR conditions34 and
the mixtures of KIR-allele–specific primers kindly provided by D. Senitzer
(City of Hope National Medical Center, Duarte, CA). The presence of
selected alleles was confirmed by using primers and PCR conditions
described by Hiby et al.35 As a quality control of our KIR genotyping
procedures, we used cell lines with known KIR genotypes (NK/KIR Phase
II QC Reference Panel, International Histocompatibility Working Group,
Seattle, WA). HLA-I typing was determined by PCR using the commercial
kit from One Lambda (Dynal Biotech, Oslo, Norway).
Statistical analysis
Data are expressed as the mean plus or minus the standard deviation (SD).
Nonparametric Mann-Whitney and Fisher exact tests have been used when
appropriate. Statistical significance was accepted for P values below .05.
Results
Immune-phenotypic analysis of circulating T lymphocytes
bearing molecules belonging to the IRS in patients with PNH
In order to identify cells with potential autoreactivity that may be
responsible for the depletion of GPI cells in PNH, we first stained
PBMCs from patients with PNH (Table 1) with a panel of
monoclonal antibodies directed against different cell-surface mark-
ers, including CD3, CD4, CD8, and CD45. No significant differ-
ences were found in this respect between patients with PNH and
healthy donors (data not shown). Since it has been recently
suggested that in autoimmune diseases CD3IRS T cells may be a
subset of lymphocytes that is expanded,13-15,22,25 we next analyzed
the expression of some members of IRS such as CLIR (CD94) and
KIR2D (CD158a/h and CD158b/j) together with CD3 (Figure 1A).
In patients with PNH we found a slight but not statistically
significant increase (Mann Whitney, P  .09) in the percentage of
T cells expressing IRS (CD3IRS). The absolute number of T
CD3IRS cells in most patients with PNH was similar to that in
healthy donors (Mann Whitney, P  .4; Table 2). On the other
hand, the absolute number of NK cells (CD3IRS) was markedly
reduced in patients with PNH (Table 2; Mann-Whitney, P  .002
for CD3KIR2D and P  .006 for CD3CLIR).
The number of lymphocytes that fail to express the GPI-
anchored protein CD59 is much lower in these patients than the
number of CD3IRS cells (not shown). We infer that they do not
belong to the PNH clone.
Further characterization of CD3IRS cells from patients with
PNH demonstrates that they expressed CD8 and CD57 (Figure 1B).
This finding suggests that CD3IRS cells may have a cytolytic
function. Indeed, CD8CD57 T cells with morphologic features
of large granular lymphocytes (LGLs) have been reported in
patients with PNH.36-38 The granules of LGLs are known to contain
perforins, and we have confirmed that in patients with PNH,
CD3IRS T cells express perforins in their cytoplasm (not
shown). In addition, by using antibodies specific for individual
V	TCR families, we have found considerable heterogeneity of
IRS T cells within individual patients and among different
patients (data not shown).
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The engagement of IRS molecules on IRS T cells from
patients with PNH triggers a powerful cytolytic activity
Lymphocytes can express 2 different isoforms of IRS, one of which
is of the activating type and the other of the inhibiting type with
respect to cytolytic function.15-18,39 Thus, we analyzed the function
of IRS in T cells from patients with PNH. To address this point, we
used a redirected killing assay. In this assay, the engagement of the
corresponding molecule by an appropriate (anti-IRS) mAb acts
both as a bridge between the Fc receptor of P815 cells and a
surface molecule on T cells and as a cross-linking device that
triggers the function of T cells themselves. In general, among
PBMCs, the CD3CD16 NK cells, on which IRSs have been first
described, are the most potent cytolytic effector cells.15-17 In order
to minimize interference in this assay by NK cells, we selected
those samples with a low number of NK cells. We found that ex
vivo–isolated PBMCs from 2 patients with PNH, incubated with
either anti-KIR or anti-CLIR mAbs in a redirected killing assay,
displayed a strong lytic effect against the target cells, indicating
that their IRSs are predominantly of the activating type (Figure 2).
When we used the same assay to test highly purified IRS T
cells activated by IL2 from patients with PNH (n 
 4), we
observed that either anti-KIR or anti-CLIR mAbs induced a strong
lytic activity (data not shown). Taken together, these findings
indicate that, in patients with PNH, T cells are equipped with
activating IRS.18-20
T-cell clones from patients with PNH mainly express activating
isoforms of IRS molecules
In order to determine the relative proportions of activating versus
inhibiting isoforms of IRS present on T cells in patients with PNH,
we proceeded to isolate T-cell clones. This was done by purifying
CLIR cells from patients with PNH and healthy donors by
positive immune-magnetic selection using anti-CLIR mAb. CLIR
cells were cloned by limiting dilution and cultured with IL2.28,29
The percentage of CD3 cells among newly isolated CLIR cells
ranged from 80% to 95%. The cloning efficiency was lower (25%)
in patients with PNH than that found with CD3CD8 or
CD3CD4 T cells from healthy donors (70% and 95%, respec-
tively), but it was similar to that of CLIR cells from healthy
donors (27%; data not shown). As expected, the large majority of
these T-cell clones, whether derived from patients with PNH or
from healthy donors, expressed CLIR, whereas only a minority
expressed KIR molecules (not shown).
In a redirected killing assay, a given clone was classified as
being of the activating type when anti-KIR or anti-CLIR mAb
triggered cytolysis of P815 at an E/T ratio of 2:1, whereas a clone
was classified as being of the inhibiting type if it inhibited lysis of
P815 at an E/T ratio of 20:1.
We found that the large majority of CD3IRS T-cell clones
from patients with PNH expressed activating isoforms of IRS
(Figure 3). In some CD3IRS T-cell clones, both KIR and CLIR
were of the activating type, whereas other T-cell clones bore
activating CLIR but inhibiting KIR or vice versa (not shown).
Twenty-four of 45 of the T-cell clones derived from patients with
PNH bore only KIR of the activating type (from PNH5, 12 CD158h
[KIR2DS1] and 2 CD158j [KIR2DS2] of 23 KIR clones; from
PNH6, 5 CD158h [KIR2DS1] of 10 KIR clones; from PNH7, 5
CD158j [KIR2DS2] of 12 KIR clones). Forty-five of 65 T-cell
clones bore CLIR of the activating type (17 from PNH5, 13 from
PNH6, and 15 from PNH7). By contrast, in healthy donors T-cell
clones bearing the activating isoforms of these 2 IRSs were very
rare (only 1 of 21 and 2 of 43, respectively, bore either KIR or
CLIR of the activating type; Figure 4A; Fisher exact test,
P  .001).
The majority (about 90%) of clones from patients with PNH
bearing activating IRS were TCR	 and a few were TCR. These
findings indicate that T-cell clones expressing activating IRS are
present with high frequency in patients with PNH, whereas they are
an exception in healthy donors.13-15
The engagement of activating IRS on IRS T-cell clones from
patients with PNH induces production of high levels of IFN-
and TNF-
Given the expression of activating IRS on T-cell clones derived
from patients with PNH, we further analyzed whether the ligation
of these IRSs lead to the production of cytokines potentially
involved in the regulation of hematopoiesis. Indeed, it has been
shown that IFN- and TNF- may play a key role in suppressing
Figure 1. Immune phenotypic analysis of circulating lymphocytes in PNH patients. (A) Expression of IRS members on peripheral-blood T lymphocytes from a patient with
PNH. Peripheral-blood mononuclear cells isolated from patient PNH5 (Ai-v) or healthy donor HD3 (Avi-x) were stained with either anti–pan-KIR2D mAb (Aii, Avii),
anti-CD158a/h mAb (Aiii, Aviii), anti-CD158b/j mAb (Aiv, Aix), or anti-CLIR (CD94) mAb (Av, Ax) and anti-CD3 mAb (Aii-Av, Avii-Ax) followed by anti-isotype specific goat
antimouse antiserum PE-conjugated (for anti-IRS mAbs) or FITC-conjugated (for anti-CD3 mAb). Samples were run on a FACSort and at least 10 000 events were analyzed
with the CellQuest computer program (Becton Dickinson). Panels Ai and Avi were stained with an unrelated mAb followed by the second reagent. Results are expressed as Log
green fluorescence intensity versus Log red fluorescence intensity in arbitrary units (au). (B) IRS T cells in patients with PNH have features of cytotoxic T cells.
Peripheral-blood mononuclear cells (PNH5) were stained with PE-conjugated anti-CD94 mAb, PerCP-conjugated anti-CD3 (Bi), and either FITC-conjugated anti-CD57 (Bii,
Biv) or anti-CD8 (Biv, Biii) mAb. Samples were run on a FACSort and analyzed with the CellQuest program. R1 and R2 regions (Bi), corresponding to CD3CD94 and
CD3CD94 cells respectively, were depicted to analyze the third color (CD57– or CD8–FITC-conjugated; Bii-Bv). Results are expressed as Log PerCP fluorescence intensity
versus Log red (PE) fluorescence intensity in arbitrary units (au) (Bi) or Log green (FITC) fluorescence intensity versus number of cells (Bii-Bv). Similar proportions of the
different T-cell subsets were found in 3 additional patients with PNH analyzed.
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hematopoiesis in AA.40-44 To analyze whether T-cell clones bearing
activating IRS were able to produce IFN- and TNF-, we stained
these clones with either anti-CLIR or anti-KIR mAbs; thus, these
clones were incubated for 24 hours at 37°C on GAM-coated plates
to achieve the cross-linking of the corresponding IRS. As shown in
Figure 5, both IFN- and TNF- were produced by IRS T-cell
clones upon the engagement of either CLIR or KIR on the cell
surface. It is of note that the amount of IFN- or TNF- released in
culture supernatant was comparable to that elicited by the engage-
ment of the CD3/TCR complex achieved by using anti-CD3 mAb,
in the same experimental system. T-cell clones that bore only one
member of IRS of the activating type were able to produce the
IFN- and TNF-A cytokines only when the corresponding receptor
was engaged by the specific mAb (data not shown). These findings
suggest that activating IRS, when appropriately engaged by the
corresponding natural ligand, can induce not only activation of the
cytolytic machinery, but also the release of cytokines, which may
play a role in regulating hematopoiesis.
T cells expressing activating IRS lyse target cells bearing the
cognate IRS counter-receptors
721.221 cells do not express HLA class I molecules but, once
transfected with HLA-G, they will express HLA-E, the counter-
ligand for CD94/NKG2-presenting HLA-G–derived peptides. When
we exposed 721.221 lymphoblastoid cells transfected with HLA-G
to T-cell populations from patients PNH6, PNH7, and PNH11, who
expressed the CLIR CD94/NKG2 of the activating type, we
obtained lysis in all 3 cases (Figure 5). Addition of either anti–HLA
class I or anti-CD94 mAb to the cytolytic assay strongly inhibited
lysis (Figure 5A-C). To determine that also activating KIR-
expressing T cells lyse cells bearing KIR ligand, we selected T-cell
clones from patients with PNH that express only one activating
KIR. Clone B25.5 CD158j (KIR2DS2) from patient PNH7
killed 721.221 cells transfected with the counter-ligand HLA-Cw3
allele (Figure 5D); and clone C15.10 CD158h (KIR2DS1)
from patient PNH5 killed 721.221 cells transfected with the











Sample 5 98 91.6 2.9 — — —
Sample 3 — — — 31.3 27.3 3.1
PNH2
Sample 2 195 69 20.6 — — —
PNH3
Sample 5 51 30.6 3.7 — — —
Sample 3 — — — 64 42 4.8
PNH4
Sample 1 55 10 9.2 — — —
PNH5
Sample 2 52.5 206 3.8 — — —
PNH6
Sample 4 70.2 10 8.3 — — —
Sample 2 — — — 115.5 9.5 12.7
PNH7
Sample 4 61.8 80.3 5.8 — — —
Sample 2 — — — 112.5 87 8.4
PNH8
Sample 2 57.5 69.5 3.8 — — —
PNH9
Sample 3 71.3 174.7 5 — — —
Sample 1 — — — 87 204 6.9
PNH10
Sample 1 29 10 2.9 — — —
PNH11
Sample 4 151.3 111.8 15.3 — — —
Sample 3 — — — 177.3 73.0 17.0
PNH12
Sample 1 87 34 9.4 67 24 7.2
PNH13
Sample 1 31 27 2.6 94 56 7.9
Mean  SD (range) 81.8  47.0 (31-195) 76.2  62.7 (10-206) 7.5  5.5 (2.6-20.6) 96.3  43.7 (31.3-177.3) 65.4  61.7 (9.5-204.0) 8.5  4.4 (3.1-17.0)
Healthy controls*
Mean  SD (range) 63  36 (19-171) 192  155 (8-690) 4.3  2.4 (1.3-11.4) 102  71 (15-309) 214  155 (9-666) 6.8  4.7 (1.0-20.6)
Peripheral-blood lymphocytes were isolated from the indicated patients. Samples of blood were collected at about 3 months from one to another during the follow-up; the
sample number indicates the number of the blood collection. Samples were stained with anti-CD3 mAb and anti-panKIR2D mAb (NKVFS1) or anti-CLIR mAb followed by
isotype-specific antimouse antiserum. At least 10 000 events for each sample were analyzed on a FACSort (Becton Dickinson). Percent of CD3 T lymphocytes that are
KIR2D or CLIR is also shown.
— indicates that the sample was not stained with the indicated antibody combination.
*For healthy controls, n 
 38 for CD3/KIR2D staining, and n 
 17 for CD3/CLIR staining.
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corresponding ligand HLA-Cw4 (Figure 5E). Again, the addition
of anti–HLA-I or anti–pan KIR mAbs inhibited by 50% to 60% the
lysis of target cells bearing the KIR counter-ligands (Figure 5D-E).
As a negative control, we found that clone A14.25, expressing the
inhibiting KIR2DL1, did not lyse 721.221 Cw4–transfected cells,
unless the inhibiting signal delivered via KIR2DL1 was impaired
by the addition of anti–HLA-I or anti–KIR mAb.
Matching activating KIR genotypes and HLA-C genotypes
in patients with PNH
IRS molecules can exert their action only when they find the
appropriate counter-ligands on target cells. Both the CLIR gene and
its counter-ligands (ie, HLA-G and HLA-E) are not known to be
polymorphic: therefore, a match for CLIR is always potentially
available. In contrast, the genes encoding KIR molecules as well as
those encoding their counter-ligands (HLA-C) are polymorphic. In
fact, each KIR allele can exert its effect only if it finds on the target
cell at least one HLA-C molecule that is a specific match for it.
Therefore, we proceeded to determine both the activating KIR
genotypes and the HLA-C genotypes of patients with PNH (Table
3). In patients PNH4, PNH5, PNH6, and PNH9, we found
KIR2DS1 and 1 or 2 of its counter-ligands (HLA-Cw4, HLA-Cw5,
Cw6). In patients PNH3, PNH5, PNH7, and PNH9, we found
KIR2DS2 and 1 or 2 of its counter-ligands (HLA-Cw1, HLA-Cw7,
HLA-Cw8). In patients PNH1, PNH2, PNH4, and PNH12, we
found the KIR2DS4 gene and its counter-ligand HLA-Cw4.45 Thus,
in 9 of 11 patients with PNH we found both the activating KIR gene
and the appropriate HLA-C allele, so that target cells bearing the
latter would be susceptible to KIR-mediated killing. We note that
the 2 remaining patients (PNH11 and PNH13) share the KIR2DS4
gene, for which a possible alternative (non-MHC) counter-ligand
has been recently suggested.46
Different susceptibility to lysis of GPI versus GPI cells
In patients with PNH there is an expansion of hematopoietic cells
lacking GPI-linked molecules.47-50 This is thought to result not
from an intrinsic growth advantage of GPI precursors, but rather
from negative selection against GPI precursors by autoreactive
cells.47-52 Therefore, we next tested whether IRS T cells from
patients with PNH would exert a different spontaneous cytolytic
activity against GPI versus GPI K562 cells. As shown in Figure
6, the cytolytic activity exerted by IRS T cells from 3 different
patients with PNH against GPI K562 was consistently higher
(ranging from 15% to 55%), at different E/T ratios, than that
observed using GPI K562 cell line. It is well known that the
binding between LFA-1 on effector lymphocytes and intercellular
adhesion molecule-1 (ICAM-1) expressed on target cells plays a
key role in triggering cytolytic activity.53-55 Pretreatment of cells
Figure 2. Peripheral-blood mononuclear cells from patients with PNH have
strong cytolytic activity. Peripheral-blood mononuclear cells were isolated from
either patients with PNH (A) or healthy donors (B) and their cytolytic activity was
analyzed in a 4-hour redirected killing assay using the FcR murine cell line P815 in
the absence (none) or in the presence of mAbs recognizing the indicated surface
molecules. Anti-CD54 mAb was used as an isotype-matched control mAb. The PNH
donor samples (PNH6 and PNH7) used in this experiment had a low number of
CD16 NK cells (9 cells/L in PNH6 and 24 cells/L in PNH7) but sizeable
proportions of CD3IRS cells (109 cells/L in PNH6 and 112 cells/L in PNH7).
Cytolytic activity of peripheral-blood lymphocytes from 2 representative healthy
donors (H1 and H2) is shown for comparison (B). Results are expressed as %
51Cr-specific release at an E/T ratio of 10:1 mean of triplicate samples; bars indicate
standard deviation of triplicate samples. A comparable difference between PBMCs of
patients with PNH and healthy donors was found also at 20:1 and at 40:1 E/T ratios.
Figure 3. Most IRS T-cell clones from patients with PNH bear IRS of the
activating type. T-cell clones expressing IRS were derived from 3 different patients
with PNH (PNH5, PNH6, PNH7) and from 5 healthy donors (HD3, HD8, HD9, HD15,
HD19). (A) Each clone was analyzed in redirected killing assay using P815 target
cells in the presence of anti-CLIR or anti-KIR mAbs at (1) an E/T ratio of 20:1 to
identify T-cell clones bearing inhibiting IRS isoforms (f) and (2) an E/T ratio of 2:1 to
identify T-cell clones bearing activating IRS isoforms (). (B) Cytolysis by T-cell
clones obtained from patients with PNH upon the engagement of activating IRS.
Cytolytic activity of T-cell clones derived from patients with PNH was analyzed in a
4-hour redirected killing assay in the absence (none) or in the presence of anti-CLIR
or anti-KIR mAb or anti-CD3 mAb. Anti-CD54 mAb was used as an isotype-matched
control mAb. The clone A15.25 (PNH5) was CLIRKIR2DS1 (CD158h) and
B25.10 (PNH7) was CLIRKIR2DS2 (CD158j) while the clones from PNH6 A12.3
expressed only CLIR (CD94) and the clone C25.2 was CLIRKIR2DS1. All the
clones were selected for the expression of activating isoforms of either CLIR and/or
KIR. These clones are representative of 65 clones analyzed. Results are expressed
as % of 51Cr release, mean of triplicate samples; bars indicate standard deviation of
triplicate samples.
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with lymphocyte function–associated antigen 1 (LFA-1)–specific
mAbs strongly reduced lysis of both GPI and GPI K562 cell
lines, confirming that LFA-1/ICAM-1 binding is involved in
effector-target interaction. However, in the presence of anti–LFA-1
mAb, IRS T cells from patient PNH11 were still able to lyse K562
cells, but only if they were GPI (Figure 6C).
These results indicate that lack of surface GPI molecules
renders cells less susceptible to lysis mediated by cytolytic effector
T lymphocytes, suggesting that GPI-linked molecules have a
critical role in effector-target ligation.
Discussion
The classic clinical triad of PNH consists of intravascular hemoly-
sis, thrombosis, and bone marrow failure.52,53 At the molecular
level, PNH is characterized by the deficiency on the surface of
blood cells of all proteins anchored to the membrane by the
glycosylphosphatidylinositol (GPI) molecule. The absence of GPI-
linked molecules, such as CD59 and CD55, explains hemoglobin-
uria,56,57 and probably also the tendency to thrombosis.58 On the
other hand, there is no obvious explanation as to why deficiency of
GPI-linked proteins by itself ought to also cause bone marrow
failure. A plausible model has been, for some time, that an
autoimmune process is at work in PNH, as it is in idiopathic
aplastic anemia (IAA).8,40 If the auto reactive T cells involved in
this process recognize a GPI-linked protein, or the GPI molecule
itself, then GPI cells, including GPI HSCs, would be damaged
selectively; whereas GPI HSCs, if they exist, would escape
damage and be able to proliferate.59 This model has been corrobo-
rated by the finding that small GPI (ie, PNH-like) clones exist in
the peripheral blood of healthy subjects48; therefore, in PNH it is
the expansion rather than the presence of GPI cells that we need to
explain. Based on this notion, it was natural to seek evidence for
auto reactive T cells. In fact, it has emerged that skewing of the
T-cell repertoire is common in PNH,9-10 and the coexistence of
LGL leukemia and PNH in the same patient38 suggests that the T
cells responsible for bone marrow damage in PNH may belong to
the CD3CD8CD57 cell population displaying NK-like cyto-
lytic activity.15-17
NK-like T cells can express IRS molecules. In terms of their
structure, IRSs are of 2 types: the immunoglobulin (Ig) superfamily
inhibitory receptors (ISIRs), which include killer Ig-like receptors
(KIR, CD158a, b, and p50); and C-type lectin inhibitory receptors
(CLIRs),15-17 such as the CD94/NKG2 complex. An increase of T
cells expressing IRS has been reported in a range of chronic
disorders, in which they may serve to maintain memory T cells
alive, as well as in a case of pure red-cell aplasia.60
For this reason, we have systematically studied in patients with
PNH those NK-like T cells that carry IRS molecules. We have
Figure 4. IRS T-cell clones produce a high amount of IFN- and TNF-. T-cell
clones expressing IRS activating isoforms (CD3KIRCLIR clones: C3.50
[KIR2DS2, from PNH5], f; and A1.25 [KIR2DS1, from PNH6], ) were stained
with either anti-CD3, anti-KIR, anti-CLIR, or anti-CD54 (isotype-matched control
mAb) mAbs and incubated in plates precoated with goat antimouse antiserum. After
24 hours, culture supernatants were harvested and analyzed by ELISA for the
presence of either IFN- (A) or TNF- (B). “None” represents the release of either
IFN- or TNF- in the absence of any mAb. Results are expressed as mean of
triplicate samples; bars indicate standard deviation of triplicate samples.
Figure 5. CD3IRS T cells lyse target cells bearing the appropriate HLA-I
counter ligand. Polyclonal (A: PNH6; B: PNH7; C: PNH11) bulk populations
homogeneously expressing CD3 and CLIR (CD94) antigens were challenged in a
4-hour 51Cr release assay with 721.221 target cells bearing HLA-E with G peptides as
ligand for CD94/NKG2 complex of the activating type. Anti–HLA-I mAb or anti-CD94
mAb (5 g/mL) was added to the cytolytic assay to determine whether the masking of
CD94/NKG2–HLA-I interaction leads to inhibition of target lysis. (D-F) The
CD3KIRCLIR T-cell clones KIR2DS2 (D; from PNH7) or KIR2DS1 (E; from
PNH5) were used as effector cells with the 721.221 transfected with HLA-Cw3 or
HLA-Cw4 (ligands of KIR2DS2 or KIR2DS1, respectively). E/T ratio indicates
effector-target ratio. Anti–HLA-I mAb or anti-panKIR2D mAb (5 g/mL) was added to
the cytolytic assay to determine whether the masking of KIR2D–HLA-I interaction
leads to inhibition of target lysis. The CD3KIR T-cell clone expressing KIR2DL1,
the inhibiting form of KIR2D recognizing HLA-Cw4, was challenged with 721.221
target cells HLA-Cw4 transfected. In this instance, the addition of anti–HLA-I mAb or
anti-panKIR2D mAb (5 g/mL) led to triggering of lysis as the impairment of
KIR2D–HLA-I binding does not protect the target cells any more. Results are
expressed as % 51Cr-specific release, mean of triplicate samples plus or minus SD.
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observed in these patients a slight but not statistically significant
increase of the proportion of T cells bearing IRS molecules,
whereas CD3CD16 NK cells were decreased, as previously
reported.61,62 This shortage of NK cells might be part of the bone
marrow failure syndrome present in patients with PNH.63,64 On the
other hand, in most patients with PNH the absolute number of IRS
T cells was similar to that found in healthy controls. These findings
were in keeping with a qualitative rather than with a quantitative
abnormality of IRS T cells in PNH; therefore, we proceeded to
their functional characterization.
IRS molecules exist in 2 functionally different isoforms. In
healthy donors, most IRS T cells bear isoforms of IRS molecules
with inhibiting properties. In fact, their engagement inhibits
strongly cytolytic activity and cytokine production triggered via
activating receptors (ie, the CD3/TCR complex).25,26 Nevertheless,
a small proportion of IRS T cells bear isoforms of IRS molecules
with activating properties. The physiologic role of the activating
isoforms of IRS is incompletely understood, although several
hypotheses have been put forward to explain their presence on
different lymphocyte subsets.15-17,39 Expansion of these cells has
been reported in rheumatoid arthritis,24 suggesting that they may
play a role in some autoimmune process.
Unlike in healthy subjects, in patients with PNH the ligation of
IRS molecules either on freshly isolated PBMCs (Figure 3) or on
highly purified IL2-activated IRS T cells triggered cytolysis in a
redirected killing assay. This indicates that in patients with PNH
there is a marked increase in IRS T cells bearing activating
isoforms of IRS. This was corroborated by generating T-cell clones.
Indeed, from healthy subjects more than 95% of these clones were
of the inhibiting type. In contrast, under the same experimental
conditions, in patients with PNH more than 50% of IRS T-cell
clones in our redirected killing assay were of the activating type
(Figure 4A). This activating function has been more conclusively
confirmed by the finding that the engagement of the activating IRS
with the appropriate HLA counter-ligands (HLA-E with G peptide
for CLIR; HLA-Cw4 for KIR2DS1; HLA-CW3 for KIR2DS2)
triggered the cytolytic activity of IRS T cells (Figure 5). The
counter-ligand of the activating CLIR is potentially present in all
individuals, whereas activating KIR alleles recognize specific
HLA-C alleles. In this respect, our analysis has shown that in most
patients with PNH, activating KIR isoforms are properly matched
with their HLA-C counter-ligands (Table 3). Although we cannot
positively state that HLA-C–matched activating KIR alleles are
expressed on IRS T cells, the genotype data suggest that the
cytotoxic ability of the IRS T cells could occur in vivo.
In principle, we cannot say whether the increase in IRS T cells
bearing activating IRS isoforms in PNH is a secondary or a primary
phenomenon. Earlier reports from other groups and from our group
have not revealed GPI cells to be less sensitive than GPI cells to
T-cell65,66 or NK-mediated lysis.33,66 Now we have found that a
specific T-cell subset (ie, IRS T cells obtained from patients with
PNH) shows NK-like cytolytic activity to which GPI K562 cells
are more sensitive than GPI K562 cells. If this difference applies
Figure 6. IRS T cells from patients with PNH kill more efficiently GPI than
GPI cells. Cytolytic activity of IRS T cells from 3 different patients with PNH (A:
PNH6; B: PNH7; C: PNH11) against GPI K562 cell line or its GPI counterpart
(KCRN) was analyzed in a 4-hour 51Cr release assay at the indicated effector-target
(E/T) ratios. Anti–LFA-1 mAb (5 g/mL) was added to the cytotoxic assay in order to
block the contribution of LFA-1/ICAM-1 interaction to the activation of T cells. As the 2
K562 cell lines differ from each other for the expression of GPI-linked molecules, this
shows the relative contribution of GPI molecules to target-cell lysis. Results are
expressed as % of 51Cr release, mean of triplicate samples plus or minus SD.
indicates KCRN (K562 GPI-); F, KCRN (K562 GPI) plus anti-LFA-1 mAb; Œ, K562
(GPI); f, K562 (GPI) plus anti-LFA-1 mAb.
Table 3. The genotype of activating KIR and of HLA-C
in PNH patients
Patient no. Activating KIR genotype HLA-C allele
PNH1 2DS4 04,‡ 16
PNH2 2DS4 04,‡ 07
PNH3 2DS2,† 2DS4 08,† 12
PNH4 2DS1,* 2DS2, 2DS3, 2DS4,‡ 2DS5, 3DS1 04,‡ 06
PNH5 2DS1,* 2DS2,† 2DS3, 3DS1 04,* 07†
PNH6 2DS1,* 2DS3, 2DS4, 3DS1 05,* 15
PNH7 2DS2,† 2DS3, 2DS4 01,† 07†
PNH9 2DS1,* 2DS2,† 2DS3, 2DS4, 2DS5, 3DS1 06,* 07†
PNH11 2DS4 07, 07
PNH12 2DS4‡ 03, 04‡
PNH13 2DS4 06, 15
Patients as in Table 1. The ligands of KIR2DS1 are the HLA-CLys80 (w2, w4, w5,
w6); the ligands of KIR2DS2 are the HLA-CAsn80 (w1, w3, w7, w8); the ligand of
KIR2DS4 is the HLA-Cw4; the ligands of KIR2DS3 and KIR2DS5 are still unknown.
*Positive matches for KIRDS1.
†Matches for KIR2DS2.
‡Matches for KIRDS4.15-17,45,46
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to HSCs as well, this is one plausible mechanism whereby GPI
deficiency would constitute a selective advantage for GPI HSCs,
explaining the expansion of PNH hematopoiesis in the context of
the bone marrow failure present in patients with PNH. This bone
marrow failure might be determined also by IFN- and TNF-,
cytokines that suppress hematopoiesis,40-44 produced by IRS
T-cell clones. Thus, the IRS T cells we have characterized are
good candidates for being able to damage GPI HSCs in PNH.
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